Familial juvenile hyperuricaemic nephropathy (FJHN) is an autosomal dominant renal disease characterised by juvenile onset of hyperuricaemia, gouty arthritis, and progressive renal failure at an early age. Recent studies in four kindreds showed linkage of a gene for FJHN to the same genomic interval on chromosome 16p11.2, where the gene for the phenotypically similar medullary cystic disease type 2 (MCKD2) has been localised. In this study we performed linkage analysis in additional 15 FJHN families. Linkage of FJHN to 16p11.2 was confirmed in six families, which suggests that, in a large proportion of FJHN kindreds, the disease is likely to be caused by a gene or genes located outside of 16p11.2. Haplotype analysis of the new and previously analysed families provided two non-overlapping critical regions on 16p11.2 -FJHN1, delimited by markers D16S499-D16S3036 and FJHN2, delimited by markers D16S412-D16S3116. Considering MCKD2 to be a distinct molecular entity, the analysis suggests that as many as three kidney disease genes may be located in close proximity on 16p11.2. From genomic databases we compiled integrated physical and transcription maps of whole critical genomic region in which 45 known genes and 129 predicted loci have been localised. We selected, analysed and found no pathogenic mutations in seven candidate genes. The linkage and haplotype analysis reported here demonstrates the genetic heterogeneity of FJHN. The report of integrated physical and mostly in-silico predicted transcription maps of the FJHN critical region provides a basis for precise experimental annotation of the current transcript map, which is essential for final identification of the FJHN gene(s).
Introduction
Familial juvenile hyperuricaemic nephropathy (FJHN), (OMIM 162000), is an autosomal dominant renal disease characterised by juvenile onset of hyperuricaemia, gouty arthritis, and progressive renal failure. The disease was first noted by Duncan and Dixon in 1960 . 1 More than 50 kindred originating from various ethnic groups -Caucasians (for review see 2 ) and, 3 -11 Hungarian, 12 Japanese, 13, 14 Chinese, 15 Polynesian 16 and recently also Finnish 17 and Chilean 18 have been described so far.
The pathogenesis and molecular basis of FJHN is unknown. Evidence that hyperuricaemia associated with the urate hypoexcretion is the primary event of the nephropathy was provided by McBride et al, 19, 20 who found normal renal function in 42% of children biochemically proven to have FJHN. In accordance with these results, the disease seems to result from a defect of uric acid tubular transport. Candidate proteins could be either voltage-sensitive urate transporters such as hUAT1 and hUAT2, 21 suggested urate/anion exchangers 22 or other proteins which may be involved in forming, regulating, processing, trafficking, and cell surface stability of structurally functional urate channel multimeric complex. In addition to the tubular transport defect hypothesis, Puig et al 7 suggested that uric acid underexcretion and hyperuricaemia may be a consequence of a primary renal hemodynamic disruption. Furthermore, the clinical, biochemical and histological examinations observed in FJHN are similar to those observed in diseases belonging to nephronophthisis-medullary cystic kidney disease complex, 23 and it was postulated that connection between FJHN and these diseases, particularly medullary cystic kidney disease type 2 (MCKD2), may exist. 11, 24, 25 Recent studies, 26 -28 one of them long-term, 28 have demonstrated the beneficial effect of allopurinol in ameliorating the progression of the renal disease. However the beneficial effect of allopurinol is controversial. 29 Others suggest that in patients with early stage nephropathy blockade of the renin-angiotensin system may delay the progression of renal insufficiency. 30, 31 These findings underscore the importance of pre-symptomatic diagnosis, especially in children. Pre-symptomatic detection enabling diagnosis and the commencement of early treatment is vital for affected families and will also result in preventing or delaying dialysis and ultimately, renal transplantation. Identifying the genetic defect is essential to facilitate such a diagnosis and replace the non-specific biochemical tests that depend on the accuracy of sample collection. Identifying the hypothetical defective urate transporter in FJHN may have broader relevance to a much more common disease of defective urate transport -the underexcreting gout ('primary' gout) affecting middle-aged males. It is possible that mutation and/or polymorphism in genes causing FJHN may also be implicated there.
Recently we 32 and others 11, 33 localised a gene for FJHN in four kindreds to chromosome 16p11.2, and found evidence of genetic heterogeneity of the disease. Interestingly, the FJHN locus was mapped to the same genomic interval where the gene for medullary cystic disease type 2 (MCKD2) (OMIM 603860), has been localised. 25, 34 Clinical and biochemical similarities and genomic co-localisation of both loci suggest that FJHN and MCKD2 may be a single disease entity. Alignment of all critical regions detected in these studies, however, provides two non-overlapping genomic regions delimited by markers D16S499-D16S3036 and D16S403-D16S3116, 11 and keeps the issue of the distinctness of FJHN and MCKD loci open. In this study we performed linkage analysis for FJHN in additional 15 families, and confirmed in six the previous observations of linkage of FJHN to 16p11.2, which suggests, that in a large proportion of FJHN kindreds, the disease is likely to be caused by a gene or genes located outside of 16p11.2. Haplotype analysis showed that two families mapped in this study might be aligned to the D16S499-D16S3036 interval only whereas the rest of the families may be aligned with both intervals. Considering MCKD2 as a distinct molecular entity, we hypothesise that as many as three genes located in close proximity on 16p11.2 may exist. From genomic databases we therefore compiled integrated physical and transcription maps of whole implicated genomic region (D16S499-D16S3116). We selected, analysed and excluded seven candidate genes. The results should facilitate efficient candidate gene selection and in combination with high throughput sequencing and functional genomic studies should help to resolve the molecular basis of FJHN/MCKD disease(s) in the future.
Methods

Patients
In total, 15 FJHN families (118 individuals of which 58 were affected) were enrolled in this study. Ten families are from Great Britain (GB1 -10), three from Spain (E1 -3) and two from Belgium (BE1 and BE2). The diagnosis of FJHN was based on the following criteria: autosomal dominant inheritance, hyperuricaemia, gouty arthritis which progress to renal failure. Clinical and biochemical data of the GB and Spanish patients have been described in detail previously. 2, 7, 20, 24, 27, 28 In family BE1, the first symptoms in the affected individuals were mild anaemia (Hb levels 10 g %), slowly progressive renal failure and hyperuricaemia from the age of 10 years. The patients had small, echogenic kidneys on renal echography. Terminal renal failure treated with renal transplantation developed at the age of 60 years in one of the affected males (DII.1).
In family BE2, three affected brothers developed the first symptoms of hyperuricaemia and gouty arthritis after the age of 30 years. Allopurinol treatment started at the first 
Genotype analysis
Genotyping was performed as previously described, 32 using a set of 13 microsatellite markers spanning the 13 cM of the critical region on chromosome 16p11.2. The marker order was as follows: cen-D16S499-D16S501-D16S3056-D16S3041-D16S3036-D16S3046-D16S403-D16S412-D16S3130-D16S417-D16S420-D16S3113-D16S401-tel and was based on the Marshfield Genetic Map.
Linkage analysis
Genotyping data were screened for errors using the PEDCHECK program. 35 Two point and multipoint linkage analyses, along with determination of the most likely haplotypes, were performed using the Allegro program. 36 The analysis was carried out under the assumption of a dominant mode of inheritance with a 95% penetrance, 5% phenocopy rate and 0.001 frequency of the disease allele. Marker allele frequencies were estimated from the families used in this study using the program Pedmanager http://www.genome.wi.mit.edu/ftp/pub/software/pedmanag). . To fill the existing gaps, contig ends BAC sequences were BLASTed against the Homo sapiens genomic contig sequences, high-throughput genomic sequencing (htgs) and BAC ends sequences sections of the NCBI database. Gene content was obtained either directly from annotated contigs or using the BLAST queries of unfinished genomic sequences against dbEST and protein databases.
Candidate gene analysis
Individual genes were evaluated according to knowledge or assumption of their function, evaluation of their expression profiles, and analysis of hypothetical functional domains. Upstream promotor region sequence, genomic organisation, and genomic sequence of candidate genes were obtained using pairwise BLASTN analysis of the cDNA with corresponding BAC sequences. Genomic fragments covering promotor region (about 500 bp upstream from the most cDNA 5' end) and all of the exons and intron-exon boundaries were PCR amplified from genomic DNA and sequenced as previously described. 37 All candidate genes were analysed in one proband and one unaffected family member in each family. Genetic variations were screened against SNP and UNIGENE databases.
Results
Linkage analysis
The results of a multipoint linkage analysis are shown in Table 1 and graphically in Figure 1 . We calculated the HLOD score, allowing for genetic heterogeneity by maximising the score over the parameter, representing the proportion of families in the sample demonstrating genetic linkage of the disease to the region of interest. A maximum HLOD score of 1.6137 was obtained at markers D16S3041-D16S3036 for a=0.374. In order to determine the statistical significance of this finding, one needs to subtract 0.3 from the maximum HLOD value, as recommended by Terwilliger and Ott, 38 to adjust for maximisation of the score over two parameters (and the recombination fraction). It is then possible to use the well-known property of asymptotic convergence of the w 2 distribution and two times natural logarithm of the odds ratio. After the adjustment, HLOD of 1.6137 corresponds to a w 2 of 6.05 (one tail P=0.007).
Thus our finding confirms the previous observations of linkage of FJHN to 16p11.2.
11,32,33
However, linkage to 16p11.2 may be excluded at the LOD= -2 level for families BE1 and GB4, while some of the other families also have negative LOD scores (without reaching the -2 level) throughout the candidate region. The value of a=0.374 implies that genetic linkage between FJHN and 16p11.2 exists in only 37% of the analysed families. Thus, while confirming linkage of FJHN to the region, our analysis provides further evidence of heterogeneity and shows that a large proportion of FJHN cases are likely to be caused by genes located outside of 16p11.2.
Haplotype analysis
Haplotype analysis showed consistent segregation of 16p11.2 haplotypes and the FJHN phenotype in six of the families (BE2, GB2, GB3, GB8, E1, E3). Thus, six out of 15 families (40%) appear to have haplotypes consistent with linkage to FJHN, providing another estimate of the degree of genetic heterogeneity of the disease. However, the haplotypes segregating within individual families are not shared across families, nor is any single allele at any of the linked markers shared across families.
Pedigrees of these families are shown in Figure 2 . We have aligned detected recombination events with critical regions delimited by haplotype analyses in all the FJHN and MCKD families linked to chromosome 16p11.2 region so far (Figure 3 ). This alignment provides two genetic intervals -D16S499-D16S3036 (FJHN1) and D16S412-D16S3116 (FJHN2) delimited by critical recombinations detected in Belgian 11 and Japanese 33 families. From eight haplotypes 39 Sequence analysis showed heterozygous transition c1305A-G located in 3'UTR in one of the patients. This polymorphism was reported in dBSNP previously.
GPRC5B (G protein-coupled receptor) UniGene Cluster Hs.242407 is a member of type 3 GPRC family. The specific function of this protein is unknown; however, it may mediate the cellular effects of retinoic acid on the G protein signal transduction cascade. 40 Seven sequence variants were detected in GPRC5B. Three single base pair deletions were present homozygously in both patients and controls suggesting the sequencing error in genome databases. Three heterozygous single base pair substitutions: g1756A-G, g11749G-A and g1086T-C were found in non-coding regions of both patients and controls. Homozygous silent transition c804C-T was found in a control.
Ks-1 (kidney specific protein 1, Sa protein), LOC123876, is a human homologue of rat hypertension associated protein which exhibits a unique tissue-specific expression exclusively in mature kidneys and livers. A recent study identified the protein as a medium-chain acyl-CoA synthetase. 41 Six sequence variants were detected in the Ks-1 gene.
Two transitions, c340G-A and c428T-C, changing 114Gln-Lys and 143Leu-Ser, respectively, transversion g1166C-A, and a homozygous single base pair deletion g3385delT were found in both patients and controls. Two heterozygous transitions, silent c438G-A (146 Leu-Leu) and g3384C-T, were found in both patients and controls.
Ks-2 (kidney specific protein 2), MACS1 (Butyryl Coenzyme A synthetase 1), UniGene Cluster Hs.98732, is localised in an opposite transcriptional direction in close proximity to the Ks-1 gene. Both rat and mouse homologues showed kidney and liver specific gene expression. 41 Three sequence variants, silent transitions c45T-C and c720G-A and c314insT were detected in Ks-2 gene. All of these variants were homozygous in both patients and controls.
CRYM (mu-crystalline homologue-NADP-regulated thyroid hormone binding protein), UniGene Cluster Hs.924, is responsible for most of the intracellular high-affinity T3 and T4 binding in the kidney and other thyroid hormone-responsive tissues. Thyroid hormone homeostasis plays an important role in kidney growth, renal haemodynamic, tubular function and electrolyte excretion, and association of hyperuricaemia with both hypothyroidism 42 and hyperthyroidism 43 has been reported. Three single base pair substitutions located in non-coding regions were detected in the CRYM gene. Two heterozygous substitutions, g2395C-G and g2646T-C, and one homozygous transition g16287T-C were found in both patients and controls.
KIAA1203 UniGene Cluster Hs.16953 is expressed in kidney and contains ubiquitin carboxyl-terminal hydrolase family two domain which may function, through proteosomal pathway, as a regulator of the amiloride-sensitive epithelial Na(+) channel SCNN1, 44 whose two subunits, SCNN1B and SCNN1G are located in KIAA1203 in close proximity on 16p11.2. Three single base pair substitutions were found in the KIAA1203 gene. The transversion c1463T-G changing 488Leu-Arg was found to be both homozygous and heterozygous in patients and controls. The transition c12476G-A changing 822Asp-Asn was homozygous in one of the controls. The transition g14188G-A was found to be heterozygous in both patients and controls.
SCNN1G (gamma subunit of the amiloride-sensitive epithelial sodium channel ENaC), UniGene Cluster Hs.3112, is a protein which mutations result in Liddle's syndrome or pseudohypoaldosteronism type I. It is suggested that variants in this gene may play a role in the pathogenesis of more common forms of human hypertension. 45 Twenty sequence variants were found in SCNN1G
gene. Three resulted in amino acid substitution c532T-A (178Trp-Arg), c1504C-G (502Pro-Ala) and c1840T-C (614Ser-Ala), and were found to be homozygous in both patients and controls. Five heterozygous silent transitions, c387T-C, c474T-C, c549C-T, c636C-T, and a homozygous c825T-C transition were in the coding region of the gene in both patients and controls. Two homozygous substitutions, 7c106C-G and 7c31G-A were found in the 5'UTR in both patients and controls. Of 10 substitutions located in non-coding region of the gene, six 7173ex1G-A, 799ex3T-C, +29ex9T-C +33ex11T-G, 77ex11G-A and 749ex12A-G were heter-ozygous and four substitutions 793ex2G-C, 749ex2A-G, 74ex2G-C and +8ex4 were homozygous in both patients and controls. A summary of all the genetic variants found is shown in Table 2 .
Discussion
Linkage analysis
The results of the linkage analysis confirm the already demonstrated linkage of FJHN to chromosome 16p11.2. However, the results also show that there is significant heterogeneity underlying the disease. On the basis of the 
maximum HLOD score, we estimate that the proportion (a) of families segregating to a gene linked to 16p11.2 is 0.37. However, the parameter a maximised under the hypothesis of heterogeneity should be interpreted as the proportion of individuals in the overall sample that belong in families segregating the linked gene, rather than simply the proportion of families segregating the gene. Hence, the estimate will be influenced by the relative size of families. In our sample, the biggest families (BE1, GB4 and GB6) do not support linkage to 16p11.2. Effectively, the value of a=0.37 is likely to be an underestimate.
Haplotype analysis
As an alternative approach, investigation of haplotypes segregating within individual families reveals that 40% of the families have haplotypes consistent with linkage to the investigated region. This value, in turn, is likely to be an overestimate, since some of the families are small and are likely to support linkage by random chance. Nevertheless, by combining the above approaches we are able to estimate that, within our sample, between 37 and 40% of FJHN cases are explained by linkage to 16p11.2. In an earlier study 32 we found that two out of three FJHN families of Czech origin showed linkage of the disease phenotype to 16p11.2. The current results demonstrate that genetic heterogeneity of FJHN is also prevalent in other European populations. Furthermore, our haplotype analysis shows that there is no common haplotype or allele segregating with the disease across families. This suggests that the disease may be the result of several independent de novo mutations, or that the underlying mutation is old and shows no linkage disequilibrium with a particular marker locus. However, since the distance between markers is of the order of 1 cM, it is likely that linkage disequilibrium between the causative mutation and the markers may have decayed even for a reasonably young mutation. A much finer marker map would be required to determine which of the above hypotheses is correct. In addition, we present an up to date synopsis of FJHN linkage results in the context of recently published FJHN/ MCKD2 studies. 11,25,32 -34 We have tried to place hypothesis of multiple loci in close proximity associated with similar phenotypes into the context of the critical region gene content. In general, a model of several loci in close proximity can be explained by defects of duplicated genes, genetic defect of proteins comprising multimeric complex (channel, receptor, signalling pathway) and genes responsible for such a complex regulation, processing, trafficking and cell surface stability. Evaluating the genomic structure and gene content, justification for the above hypothesis may be seen in the following features of the critical region; (1) presence of duplicated sequence tracts distributed throughout the parm of chromosome 16; 46 (2) co-localisation of the amiloride-sensitive epithelial sodium channel (ENaC) subunits SCNN1B and SCNN1G and of the ENaC possible regulators such as ubiquitin carboxyl-terminal hydrolase KIAA1203, elongation factor-2 kinase and protein kinase PRKCB1; (3) presence of several genes involved in kidney G proteincoupled receptor signalling and microtubule-dependent vesicle transport such as GPRC5B, MIR16, LOC124724, ARL6IP, COG7, GGA, LOC90404, dynein, ERN and RICH1; (4) presence of genes involved in regulated protein degradation such as polo-like kinase PLK, KIAA1203 or LOC123803; and (5) presence of genes involved in podocyte formation -GGA and ARL6IP. The gene content analysis showed that the delimited chromosomal region contains a number of genes, which may contribute important kidney specific structural units or regulatory functions. Since we have not found evidence for the presence of the urate transporter, we focused on some of the genes which might be involved in G-protein signalling, regulated protein degradation, thyroid hormone homeostasis or which were found to be associated with hypertension.
Candidate gene analyses
Following the sequence analysis of two genes localised within the critical region -uromodulin and SAH, 24 we have analysed seven more candidate genes. In all of the genes no 'classic' deleterious mutations were detected within the promotor regions, exon/intron junctions and coding sequences. This finding however cannot completely rule out the involvement of those genes in the disease development. The transcription of any of those genes can be greatly affected by mutations in distant promotor regions or by intronic mutations affecting mRNA processing. The cDNA studies, which would be very useful in this respect, could not be performed since we have no affected kidney tissue biopsies available.
In summary, FJHN is a genetically heterogeneous disease. To elucidate its molecular basis, further efforts must be aimed at better clinical characterisation of FJHN/MCKD patients. Affected families must be re-evaluated and followed to determine whether the disease is manageable by allopurinol and whether and when cysts occurred. Importantly, members of all three GB kindreds showing linkage in this report and identified prior to the onset of severe renal disease have been treated successfully with allopurinol -in the case of GB2 and three for from 20 to 37 years. 27, 28 Further gene mapping efforts must be focused on both refining the 16p11.2 locus and discover other FJHN loci in families not linked to 16p11.2. In this regard, it is of interest that kindred GB4, with a history of cysts at biopsy and phenotypically identical with MCKD2, has been found recently (following the onset of diabetes type 2) to have a defect on 17q involving the hepatocyte nuclear factor 1b gene (Bingham et al, personal communication). Further studies must also be focused on experimentally confined completion of physical and transcript maps of FJHN critical regions and complementary genomic and proteomic approaches. Expression profiling using the microarray technology or 2D gel protein analysis may provide useful information on candidate gene selection and pathogenesis of the disease, and attempts to obtain access to sufficient amount of affected tissues must be undertaken.
The linkage and haplotype analysis reported here further demonstrate the genetic heterogeneity of FJHN and imply the hypothesis of several loci located in close proximity on 16p11.2 as well. This situation greatly hampers the positional cloning effort and indicates that better clinical characterisation and functional approaches must be undertaken. The report of integrated physical and mostly in-silico predicted transcription maps of the FJHN critical region provides basis for precise experimental annotation of the current transcript map, which is essential for final identification of the FJHN gene(s).
